Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.
about
B Cells Are Multifunctional Players in Multiple Sclerosis Pathogenesis: Insights from Therapeutic InterventionsExploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosisCytokine-Defined B Cell Responses as Therapeutic Targets in Multiple SclerosisIntrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatmentsHeterogeneity of B Cell Functions in Stroke-Related Risk, Prevention, Injury, and RepairIs the risk of progressive multifocal leukoencephalopathy the real reason for natalizumab discontinuation in patients with multiple sclerosis?Late Occurrence of PML in a Patient Treated for Lymphoma with Immunomodulatory Chemotherapies, Bendamustine, Rituximab, and Ibritumomab Tiuxetan.Interdisciplinary Risk Management in the Treatment of Multiple Sclerosis.B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.Further understanding of the immunopathology of multiple sclerosis: impact on future treatments.Deciphering the Role of B Cells in Multiple Sclerosis-Towards Specific Targeting of Pathogenic Function.The chronically inflamed central nervous system provides niches for long-lived plasma cells.Promise, Progress, and Pitfalls in the Search for Central Nervous System Biomarkers in Neuroimmunological Diseases: A Role for Cerebrospinal Fluid Immunophenotyping.Understanding Progressive Multifocal Leukoencephalopathy Risk in Multiple Sclerosis Patients Treated with Immunomodulatory Therapies: A Bird's Eye View.Estimation of intrathecal IgG synthesis: simulation of the risk of underestimation.Regulatory B and T lymphocytes in multiple sclerosis: friends or foes?
P2860
Q26770664-AD80CD0C-8DB0-45CC-AEB7-D6D7FDEB7D8CQ26770818-4A0DA674-5E7D-440F-94AE-9411BA5ACEFEQ26771459-716B5A14-44E0-4714-9363-A7C1B0E63489Q26851694-52B939C8-8CE4-4B37-ADB7-2B07D5CA44F3Q28078211-2FE49D5E-03A6-41B5-815A-6B8890014F09Q33562701-B233DC51-03FD-450F-B8D6-3EFC58CDDD1EQ35078693-C897A677-83B2-425A-A579-7711F7768E4DQ37615119-2B622B88-4465-41A9-ADBD-3FB11D71F710Q38795434-8BEEDC2D-82CB-4345-99C1-3FAA774082A0Q38837294-FC1C7BF4-DE94-4B80-91C3-A5E160E5FE93Q47102132-80F7F1B0-4E2E-46C0-8D18-8B3CA87FC18AQ47116115-D0C7AAE2-41E0-43D7-B9FD-14223092322CQ47657261-385773AB-F3A0-4FED-9EE3-3BD15C2FB14BQ49884884-987AFB08-3F67-4957-AB7E-4B167CD399B7Q55020429-3DB67045-4655-4DBB-8FAA-B4F5ABBCCCD5Q58555322-1A8A7AD0-54C5-446F-95CA-DBF2876E3684
P2860
Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Natalizumab exerts a suppressi ...... ell function in blood and CSF.
@en
Natalizumab exerts a suppressi ...... ell function in blood and CSF.
@nl
type
label
Natalizumab exerts a suppressi ...... ell function in blood and CSF.
@en
Natalizumab exerts a suppressi ...... ell function in blood and CSF.
@nl
prefLabel
Natalizumab exerts a suppressi ...... ell function in blood and CSF.
@en
Natalizumab exerts a suppressi ...... ell function in blood and CSF.
@nl
P2093
P2860
P50
P356
P1476
Natalizumab exerts a suppressi ...... ell function in blood and CSF.
@en
P2093
Anne K Mausberg
Christoph Kleinschnitz
Clemens Warnke
Derik Hermsen
Gloria von Geldern
Hayrettin Tumani
Mark Stettner
Martin Stangel
Mathias Mäurer
Mike P Wattjes
P2860
P304
P356
10.1177/1352458514556296
P577
2014-11-12T00:00:00Z